Sofinnova Partners closes €725m fund for European life sciences

Sofinnova Partners has closed its second crossover fund at €725 million, exceeding its original target and increasing its capacity to invest in late-stage European biopharma and medtech companies.

Sofinnova Crossover II will primarily support clinical-stage businesses seeking capital to advance towards commercialisation and international expansion. The fund is expected to invest in approximately 15 companies, with selective investments in the US and other international markets.

The Paris-based venture capital firm said the fund closed at €725 million ($815 million), reflecting demand for investment in life sciences businesses progressing towards global markets.

Fund targets clinical-stage biopharma and medtech

Sofinnova Crossover II will focus on companies that have progressed beyond early-stage research and require further funding to advance clinical development, expand internationally and prepare for commercialisation.

The strategy reflects the growing role of crossover investment in supporting life sciences companies through later development stages, when capital requirements can increase substantially ahead of potential product launches.

The fund has already invested in Hemab Therapeutics, CellCentric and Neurent Medical.

Sofinnova said it expects to back approximately 15 businesses over the fund’s investment period, primarily in Europe, while retaining the flexibility to support companies in the US and other markets.

Antoine Papiernik, chairman and managing partner of Sofinnova Partners, said: “The scale of this fund reflects both the maturity of the European life sciences ecosystem and the rising demand for capital that can help companies to reach global markets.”

He added that European life sciences companies should have access to investors capable of supporting them through the later stages of growth and commercialisation.

Previous fund backed companies through major milestones

The new fund follows Sofinnova Crossover I, which supported several companies that subsequently achieved significant financing, acquisition or development milestones.

These include LimFlow, acquired by Inari Medical; Calliditas Therapeutics, acquired by Asahi Kasei; Amolyt Pharma, acquired by AstraZeneca; and Abivax, which completed a Nasdaq listing.

Sofinnova cited these outcomes as examples of its approach to supporting businesses through clinical development and towards larger-scale operations.

Kinam Hong, partner at Sofinnova Partners, said: “We continue to see exceptional opportunities emerging across European life sciences.”

He added that many companies now have the scientific strength, clinical validation and leadership teams needed to compete internationally.

European investment supports further growth

Sofinnova Crossover II is backed by the European Tech Champions Initiative (ETCI), a fund of funds managed by the European Investment Fund.

The fund adds to Sofinnova’s investment activities across the life sciences sector, with the firm operating from offices in Paris, London and Milan.

Its crossover strategy is intended to provide capital to companies at a stage when further investment can help translate clinical progress into commercial opportunities.

Mail Icon

news via inbox

Sign up for our newsletter and get the latest news right in your inbox